var data={"title":"Thyroid extract (desiccated thyroid): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Thyroid extract (desiccated thyroid): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7048?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=thyroid-extract-desiccated-thyroid-drug-information\" class=\"drug drug_general\">see &quot;Thyroid extract (desiccated thyroid): Drug information&quot;</a> and <a href=\"topic.htm?path=thyroid-extract-desiccated-thyroid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Thyroid extract (desiccated thyroid): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708983\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Weight reduction:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Drugs with thyroid hormone activity, alone or with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227348\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Armour Thyroid;</li>\n      <li>Nature-Throid;</li>\n      <li>NP Thyroid;</li>\n      <li>Westhroid;</li>\n      <li>WP Thyroid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14851204\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Thyroid Product</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14851338\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses presented as mg/kg/dose or mg/dose; closely review dosing units; adjust dose based upon clinical response and laboratory parameters. Tablet strengths may vary by manufacturer in terms of grains or mg; dosing recommendations are based on general clinical equivalencies that 1 grain = 60 mg or 65 mg; <sup>1</sup>/<sub>2</sub> grain = 30 mg or 32.5 mg; and <sup>1</sup>/<sub>4</sub> grain = 15 mg or 16.25 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital hypothyroidism:</b> Oral: 4.8 to 6 mg/kg/dose <b>or</b> 15 to 32.5 mg/dose once daily. <b>Note:</b> AAP recommends levothyroxine as the preferred treatment for hypothyroidism in neonates (AAP 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14851211\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=thyroid-extract-desiccated-thyroid-drug-information\" class=\"drug drug_general\">see &quot;Thyroid extract (desiccated thyroid): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses presented as mg/kg/dose or mg/dose; closely review dosing units; adjust dose based upon clinical response and laboratory parameters. Tablet strengths may vary by manufacturer in terms of grains or mg; dosing recommendations are based on general clinical equivalencies that 1 grain = 60 mg or 65 mg; <sup>1</sup>/<sub>2</sub> grain = 30 mg or 32.5 mg; and <sup>1</sup>/<sub>4</sub> grain = 15 mg or 16.25 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Congenital hypothyroidism: Note:</b> Guidelines do not recommend routine use of desiccated thyroid over levothyroxine monotherapy in the management of hypothyroidism (AAP 2006; ATA [Jonklaas 2014]). Infants should have therapy initiated at full doses; Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 1 to 6 months: 4.8 to 6 mg/kg/dose <b>or</b> 15 to 32.5 mg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &gt;6 to 12 months: 3.6 to 4.8 mg/kg/dose <b>or</b> 30 to 48.75 mg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 5 years: 3 to 3.6 mg/kg/dose <b>or</b> 45 to 65 mg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 6 to 12 years: 2.4 to 3 mg/kg/dose or 60 to 97.5 mg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Typical doses 1.2 to 1.8 mg/kg/dose or &gt;90 mg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Hypothyroidism:</b> Oral: Initial: 30 or 32.5 mg/day; may increase dose in 15 or 16.25 mg increments every 2 to 3 weeks until adequate replacement dose determined; initiate with 15 or 16.25 mg/day in patients with cardiovascular disease or long-standing myxedema. Usual dosage range: 60 to 130 mg/day. Inadequate response to doses up to 195 mg/day suggests noncompliance or malabsorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227333\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Armour Thyroid: 15 mg, 30 mg, 60 mg, 90 mg, 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Armour Thyroid: 180 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Armour Thyroid: 240 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Armour Thyroid: 300 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nature-Throid: 16.25 mg, 32.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nature-Throid: 48.75 mg, 65 mg, 81.25 mg, 97.5 mg, 113.75 mg, 130 mg, 146.25 mg, 162.5 mg, 195 mg, 260 mg, 325 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NP Thyroid: 15 mg, 30 mg, 60 mg, 90 mg, 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Westhroid: 16.25 mg [DSC], 32.5 mg, 48.75 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Westhroid: 65 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Westhroid: 81.25 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Westhroid: 97.5 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Westhroid: 113.75 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Westhroid: 130 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Westhroid: 146.25 mg [DSC], 162.5 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Westhroid: 195 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Westhroid: 260 mg [DSC], 325 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">WP Thyroid: 16.25 mg, 32.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">WP Thyroid: 48.75 mg, 65 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">WP Thyroid: 81.25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">WP Thyroid: 81.25 mg, 97.5 mg, 113.75 mg, 130 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg, 30 mg, 60 mg, 90 mg, 120 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227320\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14851212\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer on an empty stomach (eg, 30 to 60 minutes before breakfast) to increase absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25226398\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14851205\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Replacement or supplemental therapy in hypothyroidism of any etiology (FDA approved in all ages); pituitary TSH suppressant for the treatment or prevention of various types of euthyroid goiter, thyroid nodules, thyroiditis, multinodular goiter, and thyroid cancer (FDA approved in adults); <b>Note:</b> Not indicated for treatment of transient hypothyroidism associated with subacute thyroiditis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Clinical practice guidelines do not recommend routine use of desiccated thyroid over levothyroxine monotherapy in the management of hypothyroidism (AAP 2006; ATA [Jonklaas 2014]) or for TSH suppression in the management in thyroid cancer (ATA [Haugen 2015]). Guidelines do not recommend using TSH suppression for benign thyroid nodules in iodine sufficient patients (ATA [Haugen 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9954591\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Desiccated thyroid is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to concerns for cardiac effects; safer alternatives available (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Desiccated thyroid is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227368\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions are often indicative of excess thyroid replacement and/or hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Alopecia, cardiac arrhythmia, chest pain, dyspnea, myalgia, palpitations, tachycardia, tremor, tremor of hands</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227338\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any component of the formulation; untreated thyrotoxicosis; uncorrected adrenal insufficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227324\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated; contraindicated in patients with uncorrected adrenal insufficiency. Treatment with glucocorticoids should precede thyroid replacement therapy in patients with adrenal insufficiency (ATA/AACE [Garber 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution and reduce dosage in patients with angina pectoris or other cardiovascular disease; chronic hypothyroidism predisposes patients to coronary artery disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus and insipidus; symptoms may be exaggerated or aggravated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myxedema: Use with caution in patients with myxedema; symptoms may be exaggerated or aggravated; initial dosage reduction is recommended in patients with long-standing myxedema.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Desiccated thyroid: Contains variable amounts of T<sub>3</sub>, T<sub>4</sub>, and other triiodothyronine compounds which are more likely to cause cardiac signs or symptoms due to fluctuating levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>\n            <i>Concurrent drug therapy issues:</i></b></i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infertility (unapproved use): Thyroid supplements are not recommended for the treatment of female or male infertility, unless associated with hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight reduction (unapproved use): <b>[US Boxed Warning]: In euthyroid patients, thyroid supplements within the range of daily hormonal requirements are ineffective for weight reduction. High doses may produce serious or even life-threatening toxic effects particularly when used with some anorectic drugs (eg, sympathomimetic amines).</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25955858\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Overtreatment may result in craniosynostosis in infants and premature closure of epiphyses in children; monitor use closely. May cause transient alopecia in children during the first few months of therapy. In neonates and infants, cardiac overload, arrhythmias, and aspiration from avid suckling may occur during initiation of therapy (eg, first 2 weeks); monitor closely. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300136\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227329\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=86692&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apalutamide: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piracetam: May enhance the adverse/toxic effect of Thyroid Products. Specifically, symptoms including confusion, irritability, and sleep disorder have been described during concomitant use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Somatropin: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Thyroid Products may enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227330\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">A (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12966353\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Endogenous thyroid hormones minimally cross the placenta. Desiccated thyroid has not been found to adversely affect the fetus following maternal use during pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled maternal hypothyroidism may result in adverse neonatal and maternal outcomes (ACOG 2015). Subnormal intellectual development may occur in infants of mothers with serum thyroxine concentrations in the lowest tenth percentile at the end of the first trimester (ATA/AACE [Garber 2012]). To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy and thyroid replacement should not be discontinued during pregnancy (ACOG 2015). However, desiccated thyroid is not the preferred treatment for hypothyroidism in pregnant women because use may result in lowering serum thyroxine concentrations. Women treated with desiccated thyroid who are planning to conceive or who become pregnant should be transitioned to a preferred therapy and TSH should be monitored (ACOG 2015; ATA/AACE [Garber 2012]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14851213\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">T<sub>4</sub>, TSH, heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; growth, bone development (children); TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T<sub>4</sub> remains low and TSH is within normal limits, an evaluation of &quot;free&quot; (unbound) T<sub>4</sub> is needed to evaluate further increase in dosage. Free T<sub>4</sub> (not TSH) should be monitored to guide treatment in patients with central hypothyroidism (ATA [Jonklaas 2014]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In congenital hypothyroidism, adequacy of replacement should be determined using both TSH and total- or free-T<sub>4</sub>. During the first 3 years of life, total- or free-T<sub>4</sub> should be maintained in the upper <sup>1</sup>/<sub>2</sub> of the normal range; this should result in normalization of the TSH. In some patients, TSH may not normalize due to a resetting of the pituitary-thyroid feedback as a result of in utero hypothyroidism. Monitor closely for cardiac overload, arrhythmias and aspiration from avid suckling.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pediatric patients: Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth, and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation, accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development). Treated children may experience a period of catch-up growth. Monitor TSH and total or free T<sub>4</sub> at 2 and 4 weeks after starting treatment, every 1 to 2 months during the first year of life, every 2 to 3 months between ages 1 to 3 years, and every 3 to 12 months thereafter until growth is completed (AAP 2006; ATA [Jonklaas 2014]); repeat tests 2 weeks after any change in dosage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adults: TSH 4 to 6 weeks after treatment initiation or dose changes, 4 to 6 months after adequate replacement dose determined, followed by every 12 months thereafter (or more frequently depending on clinical situation) (ATA [Jonklaas 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14941722\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption>Thyroid Function Tests</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Lab Parameters</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Normal Range</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>4</sub> (thyroxine) serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10.1-20.9 mcg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8-14 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.8-16.6 mcg/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 month to 1 year </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.5-16.0 mcg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;1 year </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.0-12.0 mcg/dL </p></td></tr>\n        <tr>\n          <td rowspan=\"6\" align=\"center\">\n            <p style=\"text-indent:0em;\">Free thyroxine index (FTI) </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-3 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.3-26.6 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-4 weeks </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.6-20.8 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-4 months </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.4-17.9 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4-12 months </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.1-14.5 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-6 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.7-13.3 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;6 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.8-14.0  </p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>3</sub> serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Newborns</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100-470 ng/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-5 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100-260 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5-10 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">90-240 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 years to Adult </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">70-210 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>3</sub> uptake</p></td>\n          <td align=\"center\"></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">35%-45% </p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">TSH serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Cord</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-22 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-3 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;40 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-7 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;25 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;7 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0-10 micro international units/mL </p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227323\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The primary active compound is T<sub>3</sub> (triiodothyronine), which may be converted from T<sub>4</sub> (thyroxine) and then circulates throughout the body to influence growth and maturation of various tissues; exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores and stimulates protein synthesis, increases basal metabolic rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227337\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Liothyronine (T<sub>3</sub>): ~3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Thyroxine (T<sub>4</sub>): 40% to 80%; T<sub>3</sub>: 95%; desiccated thyroid contains T<sub>4</sub>, T<sub>3</sub>, and iodine (primarily bound)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: T<sub>4</sub>: &gt;99% bound to plasma proteins including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to triiodothyronine (active); ~80% T<sub>4</sub> deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">T<sub>4</sub>: Euthyroid: 6 to 7 days; Hyperthyroid: 3 to 4 days; Hypothyroid: 9 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">T<sub>3</sub>: 0.75 days (Brent, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Serum: T<sub>4</sub>: 2 to 4 hours; T<sub>3</sub>: 2 to 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (major route of elimination); partially feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14851215\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">For purposes of conversion, levothyroxine sodium (T<sub>4</sub>) 100 mcg is usually considered equivalent to desiccated thyroid 60 to 65 mg (1 grain), thyroglobulin 60 to 65 mg (1 grain), or liothyronine sodium (T<sub>3</sub>) 25 mcg (Cytomel Prescribing Information 2016). However, these are rough guidelines only and do not obviate the careful re-evaluation of a patient when switching thyroid hormone preparations, including a change from one brand of levothyroxine to another.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422282\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Armour Thyroid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $70.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $82.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $91.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $143.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $168.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (100): $126.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (100): $153.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $180.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Nature-Throid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16.25 mg (100): $19.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">32.5 mg (100): $23.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">48.75 mg (100): $25.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">65 mg (100): $27.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81.25 mg (100): $30.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">97.5 mg (100): $33.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">113.75 mg (100): $37.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">130 mg (100): $40.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">146.25 mg (100): $45.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">162.5 mg (100): $50.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">195 mg (100): $58.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">260 mg (100): $69.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (100): $55.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Westhroid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">32.5 mg (100): $23.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">65 mg (100): $27.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">97.5 mg (100): $32.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">130 mg (100): $38.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">195 mg (100): $55.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (WP Thyroid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16.25 mg (100): $26.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">32.5 mg (100): $31.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">48.75 mg (100): $33.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">65 mg (100): $36.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81.25 mg (100): $40.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">97.5 mg (100): $45.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">113.75 mg (100): $49.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">130 mg (100): $53.84</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al, &quot;Update of Newborn Screening and Therapy for Congenital Hypothyroidism,&quot; <i>Pediatrics</i>, 2006, 117(6):2290-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/16740880/pubmed\" target=\"_blank\" id=\"16740880\">16740880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists. Practice Bulletin No. 148: Thyroid disease in pregnancy. <i>Obstet Gynecol.</i> 2015;125(4):996-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/25798985/pubmed\" target=\"_blank\" id=\"25798985\">25798985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Armour Thyroid (thyroid tablet) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals, Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baskin HJ, Cobin RH, Duick DS, et al, &quot;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism,&quot; <i>Endocr Pract</i>, 2002, 8(6):457-69.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhasin S, Wallace W, Lawrence JB, et al, &ldquo;Sudden Death Associated With Thyroid Hormone Abuse,&rdquo; <i>Am J Med</i>, 1981, 71(5):887-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/7304660/pubmed\" target=\"_blank\" id=\"7304660\">7304660</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent GA, Koenig RJ. Chapter 39. Thyroid and Anti-Thyroid Drugs. In: Brunton LL, Chabner BA, Knollmann BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. New York, NY: McGraw-Hill Medical; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cytomel (liothyronine sodium) [prescribing information]. New York, NY: Pfizer; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. <i>Endocr Pract</i>. 2012;18(6):988-1028.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/23246686/pubmed\" target=\"_blank\" id=\"23246686\">23246686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. <i>Thyroid</i>. 2016;26(1):1-133. doi: 10.1089/thy.2015.0020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/26462967/pubmed\" target=\"_blank\" id=\"26462967\">26462967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. <i>Thyroid</i>. 2014;24(12):1670-1751.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/25266247/pubmed\" target=\"_blank\" id=\"25266247\">25266247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nature-Throid (thyroid USP) tablets [prescribing information]. Cave Creek, AZ: RLC Labs; April 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 86692 Version 83.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708983\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F227348\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F14851204\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F14851338\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F14851211\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F227333\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F227320\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14851212\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25226398\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14851205\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9954591\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F227368\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F227338\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F227324\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25955858\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300136\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F227329\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F227330\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F12966353\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14851213\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F14941722\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F227323\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F227337\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F14851215\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422282\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/86692|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=thyroid-extract-desiccated-thyroid-drug-information\" class=\"drug drug_general\">Thyroid extract (desiccated thyroid): Drug information</a></li><li><a href=\"topic.htm?path=thyroid-extract-desiccated-thyroid-patient-drug-information\" class=\"drug drug_patient\">Thyroid extract (desiccated thyroid): Patient drug information</a></li></ul></div></div>","javascript":null}